SCHEMBL1362264

SCHEMBL1362264

CC(C)(C)N(Cc1cccc(-c2cccc(CO[Si](C)(C)C(C)(C)C)c2)c1F)C(=O)O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 7/20 0.34
PTGER1 P34995 2/20 0.34
PTGER4 P35408 2/20 0.34
PTGER3 P43115 2/20 0.34
PTGER2 P43116 2/20 0.34
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
TACR1 P25103 1/20 0.33
HTT P42858 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CFD P00746 1/20 0.33
CD274 Q9NZQ7 1/20 0.32
FFAR4 Q5NUL3 1/20 0.32
LMNA P02545 3/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
TSHR P16473 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1362144 0.89 CD274 (0.41) FFAR1PTGER1PTGER4PTGER3PTGER2
SCHEMBL1364563 0.87 LMNA (0.38) FFAR1PTGER1PTGER4PTGER3PTGER2
SCHEMBL4098806 0.83 CHRM3 (0.41) FFAR1PTGER1PTGER4PTGER3PTGER2
SCHEMBL1362409 0.83 LMNA (0.41) FFAR1MEN1KMT2AHTTL3MBTL1
SCHEMBL1363777 0.82 GRM2 (0.37) FFAR1MEN1KMT2ATACR1HTT
SCHEMBL3426719 0.80 AGXT (0.35) FFAR1PTGER1PTGER4PTGER3PTGER2
SCHEMBL1363398 0.79 MEN1 (0.39) FFAR1MEN1KMT2ANPC1RAB9A
SCHEMBL12053383 0.78 BRD4 (0.43) MEN1KMT2ATACR1BACE1
SCHEMBL1364525 0.77 PLA2G10 (0.38) FFAR1TACR1HTTLMNA
SCHEMBL1363225 0.77 TSHR (0.46) FFAR1MEN1KMT2AHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071588-B2 Dual pharmacophores—PDE4-muscarinic antagonistics GLAXO GROUP LIMITED (GB) 2011-12-06 US disclosed
US-8067408-B2 Dual pharmacophores—PDE4-muscarinic antagonistics GLAXO GROUP LIMITED (GB) 2011-11-29 US disclosed
US-20090203677-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203677-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics PDE4A, PDE4B, PDE1A FFAR1 1062/4885PTGER1 204/4885PTGER4 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.